Las Vegas, Nevada (UroToday.com) Dr. Phillip Koo gave a talk on the concept of co-managing the patient with metastatic castrate-resistant prostate cancer (mCRPC). For treatment to be standardized we need to establish consistent care, lower costs, and improved outcomes. They are known oncological clinical pathways that standardize the care processes using evidence-based medicine. In the […]
Las Vegas, Nevada (UroToday.com) In his talk at SNMMI 2019, Philip Kuo, MD, PhD, described the current status of late-stage clinical trials, and the future landscape of 177-Lutetium-PSMA targeted therapies. The prostate-specific membrane antigen (PSMA) is a transmembrane protein that is overexpressed in prostate cancer and tends to increase with disease aggressiveness (Figure 1). There […]
Las Vegas, Nevada (UroToday.com) Dr. Tanya Dorff gave an extensive overview highlighting the major changes and evolving areas in advanced prostate cancer management. Her talk focused on the non-metastatic castrate-resistant prostate cancer (m0CRPC), oligometastatic prostate cancer, and metastatic CRPC (mCRPC). In the new space of m0CRPC, there has been recent level one evidence coming from […]
Las Vegas, Nevada (UroToday.com) Dr. Philip Koo gave a talk on the role that Radium-223 currently has in the management of metastatic prostate cancer. There is data showing that the mortality increases as the disease progresses from metastases in the lymph node to bone to visceral tissue. Bone and visceral metastases have shown the worst […]
Introduction: Non-neurogenic urinary incontinence in children is a common condition that affects the quality of life for both patients and parents. Symptoms may occur in the daytime, nighttime, or both and may be the result of structural and functional anomalies. Evaluation and management of associated co-morbidities, such as constipation is critical to management. Behavioral therapy […]
Androgen deficiency of the ageing male is a clinical syndrome resulting from the low production of androgens (testosterone levels <6.9 nmol/L) with symptoms including decline in lean mass, muscle strength, increases in body mass and overall fat mass. The aim of the study is to examine the effect of a 12 week strength training intervention […]
Several studies have reported a potential association between prostate volume (PV) and prostate disease. Here, we classified the risk factors for PV among benign prostatic hyperplasia (BPH) patients. In all, 4293 BPH patients with available clinical information were enrolled. Body mass index (BMI) was obtained as weight divided by height squared. PV was calculated as […]
For men experiencing lower urinary tract symptoms (LUTS) refractory to medical therapy, there have been numerous developments in the treatment options offered for benign prostatic hyperplasia (BPH) in the recent years. Transurethral resection of the prostate (TURP) has remained the reference standard for men with prostates sized 30 cc-80 cc, while open prostatectomy is universally […]
Men with neurogenic bladder (NGB) often have concomitant erectile dysfunction and may be considered for inflatable penile prosthesis (IPP) placement. However, it is unclear if NGB is a risk factor for complications associated with IPP placement. The aim of this study is to compare surgical outcomes after IPP placement in a contemporary cohort of patients […]
Novel therapeutic modalities have been proposed for the treatment and management of erectile dysfunction (ED). Stem cell therapy (SCT) is the injection of mesenchymal stem cells or stromal vascular fractions from adipose and other tissue sources. Although SCT has been studied and reported in multiple rodent trials, few human clinical trials exist. The aim of […]
